Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 8:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 65 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Radiotracer Clear all
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Positron Emission Tomography (PET) Imaging of Cholesterol Trafficking: Clinical Evaluation of [18F]FNP-59 in Normal Human Subjects (Group 1)

NCT04532489
View directory record Official record
Conditions
Radiotracer, Hypertension, Cholesterol
Interventions
FNP-59
Drug
Lead sponsor
Benjamin Viglianti
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Jun 10, 2026, 8:42 AM EDT
Recruiting Phase 1Phase 2 Interventional

64Cu-GRIP B in Patients With Advanced Malignancies

NCT05888532
View directory record Official record
Conditions
Prostate Cancer, Renal Cancer, Urethral Cancer, Advanced Solid Tumor, Metastatic Castration-resistant Prostate Cancer, Solid Tumor, Adult
Interventions
Copper-64 labeled Granzyme B (64Cu-GRIP B), Positron Emission Tomography (PET)
Drug · Procedure
Lead sponsor
Rahul Aggarwal
Other
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Jun 10, 2026, 8:42 AM EDT
Recruiting Phase 1 Interventional

Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF

NCT03604315
View directory record Official record
Conditions
Breast Carcinoma, Fallopian Tube Carcinoma, Ovarian Carcinoma, Primary Peritoneal Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Solid Neoplasm
Interventions
Computed Tomography, Fludeoxyglucose F-18, Fluorine F 18 Fluorthanatrace, Positron Emission Tomography
Procedure · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Jun 10, 2026, 8:42 AM EDT
Completed Phase 1 Interventional

Evaluation Comparing Tau PET Radiotracers, [18F]GTP1 and [18F]PI-2620 or [18F]MK-6240 in Subjects With Normal Cognition or Prodromal to Moderate Alzheimer's Disease

NCT04566003
View directory record Official record
Conditions
Alzheimer Disease (AD)
Interventions
[18F]GTP1, [18F]PI-2620, [18F]MK-6240
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 11, 2023 · Synced Jun 10, 2026, 8:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Occupancy of Adenosine A2A Receptors Using the PET Radiotracer [18F]MNI-444

NCT05009199
View directory record Official record
Conditions
Healthy Volunteer
Interventions
[18F]MNI-444
Drug
Lead sponsor
Invicro
Other
Eligibility
30 Years and older
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 4, 2022 · Synced Jun 10, 2026, 8:42 AM EDT
Recruiting Phase 2 Interventional

Characterization of 18F-Fluciclovine PET Amino Acid Radiotracer in Resected Brain Metastasis

NCT05554302
View directory record Official record
Conditions
Brain Metastases, Brain Cancer
Interventions
18F-Fluciclovine
Drug
Lead sponsor
Baptist Health South Florida
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 30, 2025 · Synced Jun 10, 2026, 8:42 AM EDT
Recruiting Phase 1 Interventional

FTT PET/CT in Pancreatic Neuroendocrine Tumors

NCT07114939
View directory record Official record
Conditions
Neuroendocrine Carcinoma Metastatic, Pancreatic Tumors
Interventions
[18F]FluorThanatrace
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 1, 2026 · Synced Jun 10, 2026, 8:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Human Proof of Concept Study for [11C]-RO5011232 as Radiotracer and Study of the Binding of RO4917523 to Human mGlu5 Brain Receptor at Steady-State in Healthy Volunteers

NCT01483469
View directory record Official record
Conditions
Healthy Volunteer
Interventions
RO4917523, RO5011232
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Jun 10, 2026, 8:42 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Longitudinal Evaluation of a Radiotracer for Use in Tau Tracking

NCT03919669
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment
Interventions
All Subjects
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
50 Years to 85 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 2, 2023 · Synced Jun 10, 2026, 8:42 AM EDT
Completed Early Phase 1 Interventional

Evaluation of PSMA-based PET as an Imaging Biomarker in Prostate Cancer

NCT02420977
View directory record Official record
Conditions
Advanced Prostate Cancer
Interventions
Pelvic DCFPyL PET-MRI fusion or PET/MRI
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 18, 2025 · Synced Jun 10, 2026, 8:42 AM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Pharmacokinetics, Biodistribution and Radiation Dosimetry of [18F]MODAG-009 Positron Emission Tomography (PET) Radiotracers in Adult Healthy Volunteers

NCT07617688
View directory record Official record
Conditions
Healthy Adult
Interventions
[¹⁸F]MODAG-009 PET Imaging
Drug
Lead sponsor
MODAG GmbH
Industry
Eligibility
18 Years to 60 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Jun 10, 2026, 8:42 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Evaluation of a Novel Positron Emission Tomography (PET Radiotracer for TARP Gamma-8

NCT02108015
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Brain Imaging (PET), Aterial Line, Blood Sampling
Procedure
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 55 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 19, 2019 · Synced Jun 10, 2026, 8:42 AM EDT
Recruiting Phase 1 Interventional

Study Evaluating [18F]NOTA-ABY030 for Safety and Tolerability of Indeterminate Primary and/or Metastatic Disease in Head and Neck Squamous Cell Carcinoma

NCT07217028
View directory record Official record
Conditions
SCC - Squamous Cell Carcinoma, Radiotracer, Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma
Interventions
Cetuximab (EGFR inhibitor), 18F-NOTA-ABY-030, Positron Emission Tomography (PET)
Drug · Procedure
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Jun 10, 2026, 8:42 AM EDT
Recruiting Phase 1 Interventional

DK222 Study at Hopkins

NCT07140315
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Urothelial Cancer
Interventions
[18F]DK222 radiotracer
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jun 10, 2026, 8:42 AM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

A Radiotracer ([18F]FluorThanatrace) by PET/CT for the Imaging of Breast Cancer

NCT05226663
View directory record Official record
Conditions
Breast Carcinoma
Interventions
Computed Tomography, Fluorine F 18 Fluorthanatrace, Positron Emission Tomography
Procedure · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
3
States / cities
St Louis, Missouri • Philadelphia, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 14, 2025 · Synced Jun 10, 2026, 8:42 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

PET Imaging Study of 64Cu-GRIP B for Patients Receiving CD19-directed CAR-T Therapy

NCT06522932
View directory record Official record
Conditions
Non Hodgkin Lymphoma
Interventions
64Cu-GRIP B, Positron Emission Tomography (PET), Optional tumor biopsy
Drug · Procedure
Lead sponsor
Michael Randall
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 28, 2025 · Synced Jun 10, 2026, 8:42 AM EDT
Terminated Phase 2 Interventional Results available

18F-DCFPyL PET/CT in Hepatocellular Carcinoma

NCT05009979
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
F18-FDG, MRI, CT, F18-DCFPyL, Tumor biopsy
Drug · Device · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 27, 2025 · Synced Jun 10, 2026, 8:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Radiolabel ADME (Absorption, Distribution, Metabolism, and Excretion) Study Of [14C] PF-00868554 In Healthy Adult Male Subjects

NCT00823745
View directory record Official record
Conditions
HCV
Interventions
[14C]-PF-00868554
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Mar 8, 2009 · Synced Jun 10, 2026, 8:42 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Serotonin Transporters in Alcoholism

NCT00085865
View directory record Official record
Conditions
Alcoholism
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jun 10, 2026, 8:42 AM EDT
Completed Early Phase 1 Interventional

Preliminary Evaluation of Uptake in Bone Metastases and Biodistribution of [68Ga]P15-041

NCT02826382
View directory record Official record
Conditions
Prostate Cancer, Bone Metastases
Interventions
[68Ga]P15-041
Drug
Lead sponsor
Five Eleven Pharma, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 11, 2023 · Synced Jun 10, 2026, 8:42 AM EDT
Completed Not applicable Interventional

Impact of Osteopathic Manipulative Medicine on Sentinal Lymph Node Biopsy Dye and Tracer Uptake

NCT07269860
View directory record Official record
Conditions
Breast Cancer
Interventions
OMM prior to SLNB
Procedure
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 7, 2025 · Synced Jun 10, 2026, 8:42 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

A Recovery and Lifespan Study Using INTERCEPT Red Blood Cells Prepared Using the INTERCEPT Blood System for RBCs With AS-1

NCT07015437
View directory record Official record
Conditions
Healthy Subjects
Interventions
INTERCEPT Blood System for RBCs, Infusion of autologous radiolabeled RBCs
Device · Other
Lead sponsor
Cerus Corporation
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
2
States / cities
Cincinnati, Ohio • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Jun 10, 2026, 8:42 AM EDT
Not yet recruiting Phase 1 Interventional

64Cu-GRIP B in Patients With Acute Myocarditis

NCT07481136
View directory record Official record
Conditions
Acute Myocarditis
Interventions
64Cu-GRIP B is a radiolabeled peptide tracer, a copper-64 isotope bound to a peptide designed to target extracellular Granzyme B
Drug
Lead sponsor
Javid Moslehi, MD
Other
Eligibility
18 Years to 85 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Jun 10, 2026, 8:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I Study to Determine the Absorption, Distribution, Metabolism and Excretion of Esreboxetine

NCT00800956
View directory record Official record
Conditions
Healthy
Interventions
[14C]-esreboxetine
Drug
Lead sponsor
Pfizer
Industry
Eligibility
45 Years to 65 Years · Male only
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Apr 6, 2011 · Synced Jun 10, 2026, 8:42 AM EDT